July 6, 2026
View Full PaperDiagnostic, Prognostic, and Therapeutic Implications of Genetic Testing for Hypertrophic Cardiomyopathy
Key Result
Genetic testing for hypertrophic cardiomyopathy has important diagnostic, prognostic, and therapeutic implications for clinical practice and patient management.
Key Points
- This research aims to explore the diagnostic, prognostic, and therapeutic implications of genetic testing in hypertrophic cardiomyopathy (HCM).
- Extensive review of genetic testing advancements for HCM
- Assessment of genotype-phenotype correlations
- Evaluation of commercially available genetic tests for clinical use
- Identification of new HCM susceptibility genes enhancing diagnostic accuracy
- Demonstrated prognostic value of genetic testing in patient management
- Clinical integration improves therapeutic strategies for HCM patients
PICO
P
Population
Hypertrophic Cardiomyopathy
E
Exposure / Comparator
Genetic testing
Abstract
Over the last 2 decades, the pathogenic basis for the most common heritable cardiovascular disease, hypertrophic cardiomyopathy (HCM), has been investigated extensively. Affecting approximately 1 in 500 individuals, HCM is the most common cause of sudden death in young athletes. In recent years, genomic medicine has been moving from the bench to the bedside throughout all medical disciplines including cardiology. Now, genomic medicine has entered clinical practice as it pertains to the evaluation and management of patients with HCM. The continuous research and discoveries of new HCM susceptibility genes, the growing amount of data from genotype-phenotype correlation studies, and the introduction of commercially available genetic tests for HCM make it essential that the modern-day cardiologist understand the diagnostic, prognostic, and therapeutic implications of HCM genetic testing.
Expert Takes2 quotes
1/2
“For patients with HCM caused by MYBPC3 mutation, the most common genetic subtype of HCM, treatment options have been quite limited. What makes TN-201 so exciting is that it's the first therapy developed to target the genetic cause of the disease. Potentially, we can replace the faulty gene, restore patients' heart muscle function and avoid septal reduction surgery with just one infusion.”
Dr. Milind Desai, Director of the Hypertrophic Cardiomyopathy CenterCleveland Clinicgemini_groundedView source
Cite This Study
Bos et al. (Wed,) conducted a review in Hypertrophic Cardiomyopathy. Genetic testing was evaluated. Genetic testing for hypertrophic cardiomyopathy has important diagnostic, prognostic, and therapeutic implications for clinical practice and patient management.